Editas offers asymmetric upside from EDIT-401’s differentiated LDLR upregulation, but its single-asset clinical risk and $3.50 warrant financing hurdle make it a high-risk speculative buy.
Overview
Editas Medicine is a pre-commercial genome-editing company repositioned around in vivo CRISPR medicines after terminating its ex vivo cellular pipeline, including reni-cel, in late 2024. Its principal asset, EDIT-401, uses GalNAc-LNP delivery and dual-gRNA Cas9 editing to upregulate endogenous LDLR rather than knock out PCSK9 or ANGPTL3. In non-human primates, the approach produced at least a sixfold increase in functional LDLR and at least 90% mean reductions in LDL-C, Lp(a), and ApoB. **The investment is primarily a binary clinical bet on EDIT-401**, targeting approximately 1.2 million U.S. HeFH patients and a broader 70 million-person elevated-LDL-C population. Q2 2026 revenue rose 232.1% to $11.89 million and GAAP loss narrowed to $18.23 million, but the beat was driven by deferred BMS revenue and a $1.3 million restructuring benefit rather than recurring operations; R&D rose 24.8% to $20.21 million. Cash of $211.6 million supports operations into 2H 2028. Near-term catalysts are the August 2026 Australian CTN, Q1 2027 safety and biomarker data, and late-2027 topline results. The report’s 12-month consensus target is $5.50 versus $3.16, while five-year scenarios range from $0.20 to $25.11.